France· FR:68352481
IRBESARTAN EG 75 mg, comprimé pelliculé
A irbesartan product containing irbésartan, registered in France by EG LABO - LABORATOIRES EUROGENERICS, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Irbesartan is registered in 18 of 19 countries.
Countries holding a registration under ATC C09CA04 (irbesartan), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 11 of them publish a price we can compare per daily dose
Irbesartan · ATC C09CA04
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of irbesartan costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.14 in France to $0.68 in Switzerland — a ×4.7 gap.
- France: $0.14 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Irbesartan · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- CH Switzerland$0.68
- ES Spain$0.31
- IT Italy$0.26
- US United States$0.16 (acquisition cost)
- FR France$0.14
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- IRBÉSARTAN
- Manufacturer
- EG LABO - LABORATOIRES EUROGENERICS
- Country
- France (FR)
- ATC code
- C09CA04
- ATC class
- Irbesartan
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip133400938602814plaquette(s) PVC PVDC aluminium de 30 comprimé(s)EUR 3.75
- cip133400938617603plaquette(s) PVC PVDC aluminium de 90 comprimé(s)EUR 10.85
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
371 interactions on record for irbesartan.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Irbesartan · interactions on record
371 records
- 7 severe
- 128 moderate
- 3 minor
- 152 info
Most severe, free to view
- Potassium chlorideA12BA01severe
- Potassium citrateA12BA02severe
- Potassium gluconateA12BA05severe
- Potassium chlorideB05XA01severe
81 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Irbesartan in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAPROVELSanofi Winthrop Industrie, Gentilly
- SpainAPROVEL 75 mg COMPRIMIDOS RECUBIERTOS CON PELICULASanofi Winthrop Industrie
- BelgiumAprovel 75 mgSanofi Winthrop Industrie
- FinlandAprovelSanofi Winthrop Industrie
- NetherlandsAprovel 75 mg, filmomhulde tablettenSanofi Winthrop Industrie
- SwedenAprovel 75 mg Filmdragerad tablettSanofi Winthrop Industrie
- IrelandAprovel 75 mg film-coated tabletsSanofi Winthrop Industrie
- PolandAprovelSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 23 EEA countries. Names it is sold under:
- Austria · Irbepress, Irbesartan Hexal
- Belgium · Irbesartan Eg, Irbesartan Sandoz
- Bulgaria · Ирбесан, Ирбесо
- Cyprus · Converium, Irbesartan Vocate
- Czechia · Isame
- Germany · Irbepress, Irbesartan 1 A Pharma
- Denmark · Irbesartan Accord, Irbesartan Jubilant
- Spain · Irbesartán Almus, Irbesartán Alter
- United Kingdom (Northern Ireland) · Irbesartan, Irbesartan Accord
- Greece · Besartan, Irbegen
- Hungary · Irabel, Irbesartan Sandoz
- Ireland · Irbesartan Clonmel, Irbesartan Rowa
- Iceland · Aprovel, Ifirmasta
- Italy · Abesart, Irbesartan Accord
- Liechtenstein · Aprovel, Irbesartan Teva
- Luxembourg · Irbesartan Eg, Irbesartan Viatris
- Malta · Irbesartan Aurobindo Pharma (Malta)
- Netherlands · Artibesan, Irbesartan Accord
- Norway · Aprovel, Ifirmasta
- Poland · Irbesartan Aurovitas
- Portugal · Irbesartan Alter, Irbesartan Aurovitas
- Romania · Irbesartan Terapia
- Sweden · Irbesartan Accord, Irbesartan Actavis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fb7111c6-994d-4ea4-8c1d-7e197c486f1e GET /v1/drugs/fb7111c6-994d-4ea4-8c1d-7e197c486f1e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68352481",
"date_amm": "2010-06-17",
"type_amm": "Procédure décentralisée",
"numero_ue": null,
"substance": "IRBÉSARTAN",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about irbesartan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.